Table 3.
Plasma levels of LCN2, MMP9, and MMP9/LCN2 complex in different types of nAMD patients and controls
| Variable | Control (N = 43, Mean ± SD) | CNV (N = 108, Mean ± SD) | RAP (N = 32, Mean ± SD) | PCV (N = 23, Mean ± SD) | p value |
|---|---|---|---|---|---|
| Age | 73.4 ± 8.9 | 78.9 ± 7.8† | 80.7 ± 8.7† | 71.6 ± 8.9 | |
| LCN2 (ng/ml) | 153.24 ± 49.55 | 186.60 ± 71.57* | 176.08 ± 82.70 | 168.36 ± 70.68 | 0.108a |
| MMP9 (ng/ml) | 124.16 ± 63.12 | 114.42 ± 58.93 | 111.18 ± 96.94 | 126.40 ± 65.09 | 0.301a |
| MMP9/LCN2 (ng/ml) | 188.38 ± 45.12 | 176.51 ± 53.35 | 181.69 ± 66.07 | 196.29 ± 66.05 | 0.370b |
CNV choroidal neovascularisation, RAP retinal angiomatous proliferation, PCV polypoidal choroidal vasculopathy
†P < 0.05 compared to controls
*P = 0.006 compared to controls in univariate analysis
aKruskal-Wallis one-way analysis of variance on log transformed data
bOne-way ANOVA